Using dupilumab to treat hair loss in children with alopecia areata
Dupilumab in the Treatment of Pediatric Alopecia Areata
This study is looking at how a medication called dupilumab can help kids with alopecia areata, a condition that causes hair loss, by encouraging hair regrowth and making sure the treatment is safe and effective for them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11089294 on NIH RePORTER |
What this research studies
This research investigates the use of dupilumab, a monoclonal antibody, to treat pediatric patients suffering from alopecia areata, a condition that causes hair loss. The study aims to understand how dupilumab can promote hair regrowth by targeting specific immune responses associated with the condition, particularly in children with atopic backgrounds. By enrolling pediatric patients, the research seeks to provide a safer and more effective treatment option for those with significant hair loss. Participants will be closely monitored to assess the effectiveness and safety of the treatment over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with alopecia areata, particularly those with atopic conditions or high levels of IgE.
Not a fit: Patients who do not have alopecia areata or those with other forms of hair loss unrelated to immune responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for children suffering from alopecia areata, potentially restoring their hair and improving their quality of life.
How similar studies have performed: Previous studies have shown promising results with dupilumab in adult patients with alopecia areata, suggesting potential success in pediatric populations as well.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Guttman, Emma — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guttman, Emma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.